After Sotera Health announced that its subsidiaries have reached agreements to settle the more than 870 ethylene oxide cases pending against Sterigenics and will pay $408M to settle the claims, Wolfe Research analyst Mike Polark said this settlement is "far better than Street feared and far earlier than reasonable minds expected." The analyst, who contends the stock is set "to rock" with this "massive overhang effectively removed," thinks the stock is "probably worth $15-$22" per share. Polark has a Peer Perform rating with no price target on Sotera shares, which have nearly doubled to $17.20, rising 99% in morning trading.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SHC:
- Here’s What Caused Sotera Health’s (NASDAQ:SHC) Stunning Rally
- Sotera Health Announces Settlement of Ethylene Oxide Litigation in Illinois
- Sotera Health settles ethylene oxide litigation in Illinois for $408M
- Sotera Health Chairman and CEO Presents at 41st Annual J.P. Morgan Healthcare Conference
- Sotera Health to Present at the 41st Annual J.P. Morgan Healthcare Conference